Validation of a 3-gene signature of response to axitinib in patients with advanced NETs

#4128

Introduction: Axitinib in combination with SSA significantly improved ORR and PFS per central blinded radiological assessment, as compared to placebo and SSA in 253 EP-NETs in the AXINET trial. The magnitude of the benefit, however, was limited. We recently described a 3-gene tumor transcriptomic signature predictive of response to axitinib in NET patients.

Aim(s): To validate the 3-gene predictive signature in plasma and tumor samples of independent cohorts of patients.

Materials and methods: Protein levels of Protein A (Gene A of the signature) were assessed through ELISA in 182 baseline plasma samples of NET patients from the AXINET trial (99 from the discovery cohort and 83 from a validation cohort). We also validated the signature in tumor samples of an independent cohort of 29 NET patients treated with sunitinib or SSA at Hospital 12 de Octubre. The association of the signature with PFS was performed with the log-rank test and cox-regression.

Conference:

Presenting Author: Lens-Pardo A

Authors: Lens-Pardo A, Carretero-Puche C, Antón-Pascual B, Capdevila J, Benavent M,

Keywords: axitinib, sunitinib, tyrosine kinase inhibitor, predictive biomarker, signature, elisa,